(Total Views: 332)
Posted On: 04/02/2017 12:25:52 PM
Post# of 2218
$BVX part five O.K., IF WE ARE GOING TO DO IT, LET'S DO IT!
Bob Flaherty thought. Here is a bit more depth.
For starters Bovie is headquartered in Purchase, NY where CEO Robert L. Gershon is overseeing a turnaround. Most of Bovie's major operations were moved to China years ago. Now here is more about Bovie lifted from Russ's 2016 F of F comments of a year ago. "The company is actually making tremendous progress on their new surgery technology, so I have no idea why the stock is down where it is. It's not because the fundamentals of the company haven't been turning up because they have. Things are moving ahead, the technology is tremendous, it's approved, it's selling, it's taking off and here we are at a ten year low."
Bovie has two major sources of value that are poised for explosive growth: its existing business and a robust pipeline containing breakthrough medical device technologies that address huge markets. Most of these new medical device technologies, such as J-Plasma, are either ready for market entry right now or are very close to being ready, such as BVX's Seal-N-Cut vessel sealing technology.
"Pretty soon Bovie is going to be worth a great deal more money in the market place," said Russ. "
The market place doesn't understand or is not willing to acknowledge the potential of this company which is very large. I'm not talking about a $4 or $5 stock. I'm talking about a stock that could be $10 or $20."
Bob Flaherty thought. Here is a bit more depth.
For starters Bovie is headquartered in Purchase, NY where CEO Robert L. Gershon is overseeing a turnaround. Most of Bovie's major operations were moved to China years ago. Now here is more about Bovie lifted from Russ's 2016 F of F comments of a year ago. "The company is actually making tremendous progress on their new surgery technology, so I have no idea why the stock is down where it is. It's not because the fundamentals of the company haven't been turning up because they have. Things are moving ahead, the technology is tremendous, it's approved, it's selling, it's taking off and here we are at a ten year low."
Bovie has two major sources of value that are poised for explosive growth: its existing business and a robust pipeline containing breakthrough medical device technologies that address huge markets. Most of these new medical device technologies, such as J-Plasma, are either ready for market entry right now or are very close to being ready, such as BVX's Seal-N-Cut vessel sealing technology.
"Pretty soon Bovie is going to be worth a great deal more money in the market place," said Russ. "
The market place doesn't understand or is not willing to acknowledge the potential of this company which is very large. I'm not talking about a $4 or $5 stock. I'm talking about a stock that could be $10 or $20."
(0)
(0)
